3 results
Primary ObjectiveThe primary objective is to assess the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill…
To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE).To assess the primary bleeding events (PBE) of…
To assess the effect of prehospital administration of crushed tablets of prasugrel loading dose (in addition to ASA and standard care) on safety and efficacy in patients treated with primary PCI for acute STEMI with last-generation DES (Firehawk*,…